Breaking Down Harbin Pharmaceutical Group Co., Ltd. Financial Health: Key Insights for Investors

Investors looking for a clear snapshot of Harbin Pharmaceutical Group Co., Ltd. (600664.SS) will find sharp contrasts in the numbers: Q3 2025 revenue fell to CNY 3.90 billion (down 5.29% year-over-year) while trailing twelve-month revenue is CNY 15.94 billion, and 2024 annual revenue totaled CNY 16.18 billion (up 4.65% from 2023); profitability shows a slim net profit margin of 1.77% in Q3 2025 with an operating margin of 2.59% and gross margin of 26.78%, EPS of CNY 0.21 and a P/E around 19.91; balance-sheet strength includes a market capitalization of CNY 8.99 billion (Dec 12, 2025), total assets of CNY 14.08 billion, total liabilities of CNY 7.67 billion, cash and equivalents of CNY 3.63 billion against total debt of CNY 1.62 billion, a conservative debt-to-equity of 19% and an interest coverage ratio of 31.4x-while valuation metrics show a trailing P/E of 14.77, forward P/E of 12.80, P/B of 1.74 and an enterprise value-to-EBITDA of 7.95; read on to dig into revenue drivers, margin dynamics, liquidity, valuation nuances, risks such as regulatory pressure and competition, and the company's growth bets in medical protective equipment and international expansion.

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) - Revenue Analysis

• Q3 2025 revenue: CNY 3.90 billion (down 5.29% year-over-year).
• Trailing twelve months (TTM) revenue: CNY 15.94 billion (down 1.72% YoY).
• Full-year 2024 revenue: CNY 16.18 billion (up 4.65% vs. 2023).
• Revenue per employee: ~CNY 1.57 million (total employees: 10,180).
• Price-to-sales (P/S) ratio: 0.59.
• Market capitalization (as of 12 Dec 2025): CNY 8.99 billion (down 6.79% YoY).

• The FY2024 increase (+4.65%) indicates recovery or product mix gains versus 2023, but the TTM decline (-1.72%) and Q3 2025 drop (-5.29%) suggest recent weakening or seasonality effects.
• Revenue per employee (~CNY 1.57M) provides a productivity benchmark versus peers; combined with a P/S of 0.59, the market values the company below 1x sales, implying either risk discounting or undervaluation depending on margin and growth outlook.
• Market-cap contraction (-6.79% YoY to CNY 8.99B) has outpaced the modest sales decline, compressing valuation multiples.

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) Profitability Metrics

Key profitability indicators for Q3 2025 paint a mixed picture of operational resilience but weakening bottom-line performance.

• Net profit margin: 1.77% (Q3 2025), down 55.86% vs Q3 2024 - sharp contraction in net profitability.
• Operating margin: 2.59% - indicates limited earnings from core operations after operating expenses.
• Gross margin: 26.78% - healthy spread between revenue and cost of goods sold, showing product-level profitability.
• EBITDA margin: 5.83% - reflects operational cash-generation ability before depreciation, amortization, interest and tax.
• Return on assets (ROA): 3.28% - efficiency of asset utilization to generate profit.
• Return on equity (ROE): 9.75% - return delivered to shareholders on equity base.
• Earnings per share (EPS): CNY 0.21; Price-to-earnings (P/E) ratio: 19.91 - market valuation implying moderate investor expectations.

• Drivers to watch: gross margin stability vs. rising SG&A, R&D spend, interest expense, and non-operating items that can erode net margin.
• Investor considerations: reconcile strong gross margin (26.78%) with weak net margin (1.77%) to determine whether cost structure or one-off items are driving the gap.
• Valuation lens: EPS CNY 0.21 with P/E 19.91 suggests market expects recovery; monitor quarterly trend in net margin and EBITDA margin for confirmation.

For context on the company's strategic orientation and long-term priorities see Mission Statement, Vision, & Core Values (2026) of Harbin Pharmaceutical Group Co., Ltd.

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) - Debt vs. Equity Structure

• Debt-to-equity ratio: 19% - conservative leverage relative to equity base.
• Total debt: CNY 1.22 billion (reported) and alternatively noted CNY 1.62 billion in liquidity disclosures.
• Total equity: CNY 6.41 billion - underpinning book value and leverage metrics.
• Cash and equivalents: CNY 3.63 billion - yielding a net cash position when set against total debt.
• Interest coverage ratio: 31.4 - strong ability to service interest expense from operating profit.
• Current ratio: 1.44 - adequate short-term liquidity to cover current liabilities.
• Book value per share: CNY 2.227 - representing net asset value per share.

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) - Liquidity and Solvency

• Cash & short-term investments: CNY 2.74 billion (-12.32% YoY)
• Total assets: CNY 14.08 billion
• Total liabilities: CNY 7.67 billion
• Current ratio: 1.44 (sufficient short-term coverage)
• Quick ratio: not explicitly disclosed; likely similar to current ratio given low inventory/short-term debt
• Interest coverage ratio: 31.4x (strong ability to service interest)
• Short-term debt: low, supporting liquidity position

• Implication for investors: robust interest coverage and a current ratio of 1.44 reduce near-term solvency risk; the YoY cash decline merits monitoring of operating cash flow and working capital trends.
• Watch points: any continued erosion of cash reserves, changes in short-term borrowings, or material increases in current liabilities that could compress the current and quick ratios.

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) - Valuation Analysis

• Trailing P/E: 14.77 - historical earnings multiple.
• Forward P/E: 12.80 - market-implied earnings growth/expectation.
• Price-to-Book (P/B): 1.74 - market value vs. accounting book value.
• Enterprise Value / Revenue: 0.53 - how the market prices revenue on an EV basis.
• Enterprise Value / EBITDA: 7.95 - valuation relative to operating profitability.
• Market Capitalization: CNY 8.99 billion (as of December 12, 2025).
• 52-week range: CNY 3.06 - CNY 4.97 - observed price volatility window.
• Beta: 0.17 - much lower systematic volatility versus the broader market.

• Value-oriented case: Lower forward P/E vs. trailing P/E and sub-8 EV/EBITDA can indicate potential undervaluation if earnings guidance and margins hold.
• Balance-sheet context: P/B of 1.74 implies the market still assigns a premium to book equity, but not an excessive one.
• Risk/volatility: Beta 0.17 and a relatively narrow market cap suggest limited beta-driven upside in broad rallies but potential stability in downturns.

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) - Risk Factors

• Regulatory and compliance risk: The pharmaceutical sector faces stringent regulatory approvals, post-marketing surveillance, GMP inspections, and price-control policies that can delay product launches or limit pricing power.
• Competitive landscape: Intense competition from domestic generics manufacturers, multinational pharma companies, and biotech entrants increases pricing pressure and can erode market share.
• Currency and cross-border exposure: Fluctuations in USD and other currencies versus RMB impact cost of imported active pharmaceutical ingredients (APIs), licensing fees, and overseas revenue translation.
• Supply chain disruption: Dependence on key API suppliers and logistics routes creates vulnerability to raw-material shortages, quality issues, and cost inflation.
• Healthcare policy and reimbursement changes: Modifications to national or provincial reimbursement lists and tendering processes can significantly alter revenue streams and margins.
• Macroeconomic risk: Economic downturns and reduced consumer spending on out-of-pocket healthcare items can depress demand for non-essential products and OTC offerings.

• Regulatory delays: A 12-18 month delay on a new drug approval can defer peak-year revenues by >RMB 1-3 billion depending on product mix; pipeline valuation multiples typically decline 20-40% per year of delay.
• Price compression: A 5-10% reduction in average realized price (from tendering or reimbursement cuts) could reduce gross profit by roughly RMB 1.0-1.8 billion annually given current sales mix and gross margins.
• Currency shock: A sustained 10% RMB depreciation versus USD/EUR can raise API and equipment import costs; based on import exposure estimates, EBITDA could be compressed by 3-6% absent hedging.
• Supply interruptions: Short-term supply shocks for key APIs impacting 10-20% of product volume may force reliance on higher-cost alternative suppliers, compressing margins and increasing working capital needs.
• Policy shocks: Removal or repricing of a major listed drug from reimbursement programs can reduce segment revenue by tens to hundreds of RMB millions, depending on provincial coverage and patient co-pay sensitivity.

• Diversified product portfolio and mix shift toward higher-margin, specialty products to mitigate pricing risk.
• Investment in internal API capabilities and strategic supplier partnerships to reduce single-source dependencies.
• Growing R&D spend (approx. 5.9% of 2023 revenue) to support pipeline resilience, though execution and approval timelines remain key risks.
• Active treasury and hedging policies to manage currency exposure; investors should review hedge effectiveness disclosures in interim reports.
• Working-capital and inventory management metrics-monitor days inventories and payables for stress signals during supply-chain disruptions.

• Track clinical trial milestones, NDA/BLA submission dates, and local GMP inspection outcomes for pipeline products.
• Follow national and provincial reimbursement list updates and public tender results impacting major product lines.
• Review quarterly disclosures for changes in gross margin drivers, API cost trends, and one-off inventory adjustments.
• Monitor foreign-currency exposures, hedging programs, and the company's commentary on import substitution progress.
• Assess counterparty and supplier concentration-top five API suppliers and top 10 customers concentration ratios are material.

Harbin Pharmaceutical Group Co., Ltd. (600664.SS) - Growth Opportunities

• Medical protective equipment: Rapid ramp-up of PPE manufacturing can capture sustained demand from hospitals, laboratories, and government procurement channels, improving short-term cash flow while building a new recurring revenue stream.
• International markets: Exports and strategic partnerships-particularly in Southeast Asia, Africa, and parts of Europe-offer revenue upside and better utilization of existing manufacturing capacity.
• R&D investment: Increasing R&D spend to accelerate pipeline development and specialty drug launches can raise average selling prices and margins over time.
• Acquisitions: Bolt-on M&A of niche or generic players can quickly increase market share, add distribution networks, and provide immediate synergies.
• Therapeutic expansion: Prioritizing oncology, autoimmune, and specialty generics aligns with aging-population demand and higher-margin product categories.
• Digital transformation: ERP, CRM, and digital sales channels can streamline operations, reduce working capital needs, and improve customer reach.

• Target geographies for export growth: ASEAN (Indonesia, Vietnam, Philippines), MENA countries, selected African markets, and parts of Eastern Europe-focus on regulatory alignment and local partner distribution agreements.
• R&D priorities: biologics biosimilars, oncology small molecules, specialty injectables, and formulation upgrades for established generics to defend pricing.
• M&A targets: smaller domestic generics with strong regional networks, biotech startups with phase II assets, and contract manufacturing organizations (CMOs) to internalize capacity.
• Digital initiatives: e-detailing to hospitals, e-commerce for OTC and consumer health, supply-chain digitization to reduce days inventory outstanding (DIO) and improve cash conversion.